import { db } from "./db";
import { csrReports, csrDetails } from "@shared/schema";

async function seed() {
  console.log("Seeding database with sample data...");

  // First, check if we already have data to avoid duplicates
  const existingReports = await db.select().from(csrReports);
  if (existingReports.length > 0) {
    console.log("Database already has data, skipping seed");
    return;
  }

  // Sample CSR Reports
  const reports = [
    {
      title: "Aducanumab Phase 3 Study",
      sponsor: "Biogen",
      indication: "Alzheimer's Disease",
      phase: "Phase 3",
      status: "Processed",
      date: "2023-10-15",
      uploadDate: new Date("2023-11-02"),
      summary: "Phase 3 study evaluating efficacy and safety in early Alzheimer's",
      fileName: "aducanumab_phase3.pdf",
      fileSize: Math.floor(1024 * 1024 * 2.5), // 2.5 MB as an integer
    },
    {
      title: "Tirzepatide SURPASS-1 Trial",
      sponsor: "Eli Lilly",
      indication: "Diabetes Type 2",
      phase: "Phase 3",
      status: "Processed",
      date: "2022-12-04",
      uploadDate: new Date("2023-10-28"),
      summary: "SURPASS-1 trial for type 2 diabetes treatment",
      fileName: "tirzepatide_surpass1.pdf",
      fileSize: Math.floor(1024 * 1024 * 3.2), // 3.2 MB as an integer
    },
    {
      title: "Tofersen SOD1-ALS Phase 1/2",
      sponsor: "Biogen",
      indication: "ALS",
      phase: "Phase 1/2",
      status: "Processing",
      date: "2021-06-17",
      uploadDate: new Date("2023-11-05"),
      summary: "",
      fileName: "tofersen_als_phase1_2.pdf",
      fileSize: Math.floor(1024 * 1024 * 1.8), // 1.8 MB as an integer
    }
  ];
  
  // Insert reports
  const insertedReports = await db.insert(csrReports).values(reports).returning();
  
  // Add sample CSR details for the first two reports
  const details = [
    {
      reportId: insertedReports[0].id,
      studyDesign: "Randomized, double-blind, placebo-controlled, parallel-group study",
      primaryObjective: "To evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment",
      studyDescription: "This was a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Aducanumab in participants with early Alzheimer's disease.",
      inclusionCriteria: "Male and female participants aged 50-85 years, Clinical diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease",
      exclusionCriteria: "Any medical or neurological condition other than Alzheimer's Disease that might be a contributing cause of cognitive impairment",
      treatmentArms: [
        {
          arm: "Arm 1",
          intervention: "Aducanumab Low Dose",
          dosingRegimen: "3 mg/kg IV every 4 weeks",
          participants: 546
        },
        {
          arm: "Arm 2",
          intervention: "Aducanumab High Dose",
          dosingRegimen: "10 mg/kg IV every 4 weeks",
          participants: 547
        },
        {
          arm: "Arm 3",
          intervention: "Placebo",
          dosingRegimen: "Matching placebo IV every 4 weeks",
          participants: 545
        }
      ],
      studyDuration: "Total study duration was approximately 100 weeks",
      endpoints: {
        primary: "Change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 78",
        secondary: [
          "Change from baseline in Mini-Mental State Examination (MMSE) score at Week 78",
          "Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13) at Week 78",
          "Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL-MCI) at Week 78"
        ]
      },
      results: {
        primaryResults: "The change from baseline in CDR-SB at Week 78 showed a significant treatment effect in favor of Aducanumab high dose compared to placebo (difference: -0.39, p=0.0120).",
        secondaryResults: "The high dose of Aducanumab showed significant treatment effects versus placebo on all secondary clinical endpoints.",
        biomarkerResults: "Aducanumab treatment resulted in dose-dependent reduction in brain amyloid plaque levels as measured by amyloid PET."
      },
      safety: {
        overallSafety: "The overall incidence of adverse events (AEs) was similar across all treatment groups.",
        ariaResults: "ARIA-E (edema) occurred in 34% of participants in the high-dose group and 26% in the low-dose group, compared to 3% in the placebo group.",
        commonAEs: "The most common adverse events were headache, fall, and diarrhea."
      },
      processed: true
    },
    {
      reportId: insertedReports[1].id,
      studyDesign: "Randomized, double-blind, placebo-controlled, parallel-group study",
      primaryObjective: "To evaluate the efficacy and safety of tirzepatide compared with placebo in patients with type 2 diabetes",
      studyDescription: "SURPASS-1 was a 40-week Phase 3 trial that evaluated tirzepatide as a monotherapy for adults with type 2 diabetes.",
      inclusionCriteria: "Adults with type 2 diabetes inadequately controlled with diet and exercise, HbA1c between 7.0% and 10.5%",
      exclusionCriteria: "History of pancreatitis, severe gastroparesis, personal or family history of medullary thyroid carcinoma",
      treatmentArms: [
        {
          arm: "Arm 1",
          intervention: "Tirzepatide 5 mg",
          dosingRegimen: "Once weekly subcutaneous injection",
          participants: 121
        },
        {
          arm: "Arm 2",
          intervention: "Tirzepatide 10 mg",
          dosingRegimen: "Once weekly subcutaneous injection",
          participants: 121
        },
        {
          arm: "Arm 3",
          intervention: "Tirzepatide 15 mg",
          dosingRegimen: "Once weekly subcutaneous injection",
          participants: 120
        },
        {
          arm: "Arm 4",
          intervention: "Placebo",
          dosingRegimen: "Once weekly subcutaneous injection",
          participants: 113
        }
      ],
      studyDuration: "40 weeks with 4-week follow-up period",
      endpoints: {
        primary: "Change from baseline in HbA1c at Week 40",
        secondary: [
          "Change from baseline in body weight at Week 40",
          "Percentage of participants achieving HbA1c <7.0%",
          "Change from baseline in fasting serum glucose"
        ]
      },
      results: {
        primaryResults: "All tirzepatide doses demonstrated superior A1C reductions versus placebo at 40 weeks.",
        secondaryResults: "Tirzepatide led to significant reductions in body weight compared to placebo.",
        biomarkerResults: "Significant improvements in fasting serum glucose levels were observed across all tirzepatide doses."
      },
      safety: {
        overallSafety: "The most common adverse events were gastrointestinal, including nausea, diarrhea, and vomiting.",
        severeEvents: "Low rates of severe hypoglycemia were reported across all treatment groups.",
        discontinuationRates: "Discontinuation rates due to adverse events were 7% to 9% in the tirzepatide groups compared to 3% in the placebo group."
      },
      processed: true
    }
  ];

  // Insert details
  await db.insert(csrDetails).values(details);
  
  console.log("Database successfully seeded with sample data");
}

// Execute the seed function
seed().catch(console.error);